z-logo
open-access-imgOpen Access
CircPVT1 promotes progression in clear cell renal cell carcinoma by sponging miR‐145‐5p and regulating TBX15 expression
Author(s) -
Zheng Zaosong,
Chen Zhiliang,
Zhong Qiyu,
Zhu Dingjun,
Xie Yingwei,
Shangguan Wentai,
Xie Wenlian
Publication year - 2021
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14814
Subject(s) - clear cell renal cell carcinoma , gene knockdown , microrna , cancer research , carcinogenesis , cell growth , downregulation and upregulation , biology , cell , metastasis , cancer , apoptosis , renal cell carcinoma , medicine , oncology , gene , genetics
Abstract Emerging evidence revealed that circular RNAs (circRNAs) play significant roles in regulating tumorigenesis and cancer progression. However, few circRNAs were well characterized in clear cell renal cell carcinoma (ccRCC). We found that circPVT1 was significantly upregulated in ccRCC tissues and positively associated with the clinical stage. The Area Under Curve of tissue and serum circPVT1 expression in ccRCC were 0.93 and 0.86, respectively. Importantly, we demonstrated that circPVT1 promoted ccRCC growth and metastasis in vitro and in vivo. We also found that circPVT1 directly binds to miRNA‐145‐5p via the Biotin‐labelled miRNA pulldown assay and dual‐luciferase reporter assay, and miR‐145‐5p inhibitor significantly attenuated the effect of circPVT1 knockdown on ccRCC cells. Moreover, through RNA sequencing and bioinformatics analysis, we demonstrated that TBX15 was regulated by the circPVT1/miR‐145‐5p axis and predicted poor prognosis in ccRCC. These findings suggest that circPVT1 promotes ccRCC growth and metastasis through sponging miR‐145‐5p and regulating downstream target TBX15 expression. The circPVT1/miR‐145‐5p/TBX15 axis might be a potential diagnostic marker and therapeutic target in ccRCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here